Cantargia (Cantargia AB, Nasdaq Stockholm: CANTA) has updated the anticipated schedules for nadunolimab clinical studies.

Centessa Pharmaceuticals Unveils Late-Breaking Poster on Non-Human Primate Data for ORX142, a New Orexin Receptor 2 (OX2R) Agonist.

Find Therapeutics Announces FDA Approval for FTX-101 Phase 1 Clinical Trial in Chronic Optic Neuropathy Treatment.

The European Commission has authorized the use of Astellas’ PADCEV™ (enfortumab vedotin) with KEYTRUDA® (pembrolizumab) as an initial treatment for advanced urothelial carcinoma.

Yunovia revealed on the 26th that the Korean MFDS has approved the IND application for a Phase 1 MAD study of ID110521156.

Axalbion Therapeutics Begins Phase 2 Trial for Chronic Cough by Administering AX-8, a New TRPM8 Agonist, to the First Patient.

Zai Lab to Share Early Findings from Phase 1 Study of ZL-1218, a Potential Anti-CCR8 Antibody for Advanced Tumor Therapy, at ESMO Congress 2024.

The European Commission greenlights RYBREVANT®▼ (amivantamab) alongside chemotherapy for adults with advanced EGFR-mutated NSCLC after previous treatments haven't worked.

Tonix Pharmaceuticals partners with Bilthoven Biologicals to advance TNX-801 Mpox vaccine development.

Ordspono™ (odronextamab) has received approval in the EU for treating relapsed or refractory follicular lymphoma and diffuse large B-cell lymphoma.

This approval broadens the scope of the MACI® (autologous cultured chondrocytes on porcine collagen membrane) label.

Roche has announced that the European Commission has granted approval for PiaSky® (crovalimab), an innovative recycling monoclonal antibody that targets the complement protein C5.